Naz Rahman
Stock Analyst at Maxim Group
(0.22)
# 4,336
Out of 5,006 analysts
39
Total ratings
15.15%
Success rate
-40.3%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $6.56 | +204.88% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $1.90 | +268.42% | 2 | Sep 25, 2025 | |
| SCPH scPharmaceuticals | Downgrades: Hold | n/a | $5.67 | - | 4 | Aug 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.57 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.01 | +183.10% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $3.93 | +1,808.40% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $29.72 | +135.53% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.25 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.18 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.60 | +400.00% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.38 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.91 | +229.85% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $7.20 | +1,844.44% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $403.30 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.21 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.56 | +134.38% | 1 | Feb 25, 2022 |
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $6.56
Upside: +204.88%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $1.90
Upside: +268.42%
scPharmaceuticals
Aug 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $5.67
Upside: -
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.57
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.01
Upside: +183.10%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $3.93
Upside: +1,808.40%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $29.72
Upside: +135.53%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.25
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.18
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.60
Upside: +400.00%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.38
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.91
Upside: +229.85%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $7.20
Upside: +1,844.44%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $403.30
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.21
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.56
Upside: +134.38%